| OXY |
Report |
Adjusted EPS from continuing operations |
BEAT |
pred ~$1.95 vs. cons $1.88 |
MEDIUM |
| OXY |
Report |
Free cash flow before working capital |
BEAT |
pred ~$2.50B vs. cons $2.35B |
MEDIUM |
| OXY |
Report |
Worldwide production |
IN-LINE |
pred ~1.415 MMBOE/d vs. cons 1.420 MMBOE/d |
MEDIUM |
| OXY |
Guide |
Worldwide production guidance |
UNCHANGED |
guide ~1.44 MMBOE/d vs. cons 1.44 MMBOE/d (FY2026) |
MEDIUM |
| OXY |
Guide |
Capital-spending guidance |
UNCHANGED |
guide ~$5.70B midpoint vs. cons $5.70B (FY2026) |
HIGH |
| OXY |
Guide |
Midstream and Marketing adjusted pre-tax income guidance |
BETTER |
guide ~$1.30B vs. cons $1.10B (FY2026) |
MEDIUM |
| OXY |
Guide |
Principal debt target |
BETTER |
guide ~$9.50B vs. cons $10.00B (year-end 2026) |
LOW |
| OXY |
Return |
Day-1 residual (stock − beta × S&P 500) |
+2.8% |
— |
MEDIUM |
| OXY |
Return |
5-day cumulative residual |
+1.3% (FADE) |
The initial reaction should reward modest EPS and free-cash-flow beats plus faster deleveraging, but much of the upside is commodity-price-driven. Unchanged production and capital guidance, normalization of Midstream benefits, and no firm recurring buyback framework should limit out-period estimate revisions and partially fade the day-1 gain. |
MEDIUM |